Table 3. Synergistic combinations of CHM compounds or CHMs with chemotherapeutic drugs in clinical.
CHM Compounds/CHMs | Chemotherapeutic Drugs | Designs | Case Numbers | Cancers | Clinical Outcomes | Refs. |
---|---|---|---|---|---|---|
Arsenic trioxide | ascorbic acid+melphalan | prospective, multicentre, single-arm | 65 | multiple myeloma | ↑ therapeutic effect and tolerance | [104] |
all-trans retinoic acid | randomized, controlled | 61 | acute promyelocytic leukemia | ↑ quality of complete remission, the status of the disease-free survival | [105] | |
dexamethasone+ascorbic acid | a phase 2 trial. | 20 | multiple myeloma | ↑tolerance;↓ adverse events | [106] | |
Mistletoe extract | cyclophosphamide + adriamycin +cisplatin /cyclophosphamide +adriamycin +5-fluorouracil |
Prospective, Randomized, Controlled | 68 | breast cancer | ↑quality of life;↓reduce the side-effects | [107] |
cyclophosphamide +cisplatin/ifosfamide +carboplatin | A Prospective Randomized Controlled Clinical Trial | 71 | ovarian cancer | ↑ quality of life;↓reduce the side-effects | [107] | |
vinorelbine +cisplatin /mitomycine+vindesine +cisplatin | A Prospective Randomized Controlled Clinical Trial | 94 | non-small cell lung cancer | ↑ quality of life;↓reduce the side-effects | [107] | |
cyclophosphamide+methotrexate+fluorouracil | randomised, placebo-controlled, double-blind, multicentre | 272 | breast cancer | ↑ quality of life | [108] | |
cisplatin+5-fluorouracil/5-fluorouracil | randomized, controlled | 20 | ear, nose and throat carcinoma | ↑ immunological reactions, microcirculation | [109] | |
Turmeric powder | imatinib | randomized, controlled | 50 | chronic myeloid leukemia | ↑ therapuetic effect | [88] |
Astragalus polysaccharide injection | vinorelbine and cisplatin | randomized, controlled | 136 | non-small cell lung cancer | ↑ therapeutic effect, quality of life ; ↓reduce the side-effects | [110] |
Cimicifuga racemosa | tamoxifen | prospective | 50 | breast cancer | ↓ psychovegetative symptoms | [111] |
Scutellaria baicalensis | irinotecan | randomized, controlled | 44 | non-small cell lung cancer | ↓ gastrointestinal toxicity | [112] |
↑: Up-regulation
↓: Down-regulation